S 1505 · 110th Congress 2007โ€“2009, ended

Affordable Biologics for Consumers Act

Latest action · May 24, 2007 Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Progress

Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.

  1. IntroducedMay 24, 2007
  2. Passed SenateNot reached
  3. Passed HouseNot reached
  4. To the PresidentNot reached
  5. Became lawNot reached

Summary

Affordable Biologics for Consumers Act - Amends the Public Health Service Act to allow any person to submit an application for approval of a biologics license for a biosimilar, which is defined as a biological product that is claimed to be similar to a qualified biological product (the reference product). Defines a "qualified biological product" as a biotechnology-derived therapeutic biological or protein product licensed or approved under the Federal Food, Drug, and Cosmetic Act.

Allows the Secretary of Health and Human Services to approve an application for a biosimilar only: (1) for indications for which the reference product is approved; and (2) if the application conforms to the applicable final product class-specific rule and the Secretary concludes that the product is safe, pure, and potent.

Authorizes a person to request the issuance of a product class-specific rule applicable to a qualified biological product and its class.

Requires the Secretary to establish a Biosimilars Advisory Committee.

Prohibits the approval of a biosimilar until at least 14 years have elapsed from approval of the reference product.

Prohibits the Secretary from: (1) approving a product that is claimed to be similar to or the same as a reference product under any other provision of law; (2) approving another biosimilar for one year after approving the first biosimilar that relies on the same reference product; and (3) designating a biosimilar as interchangeable with (or therapeutically equivalent to) the applicable reference product.

Sets forth provisions related to patents for a reference product. Allows approval of an application for a biosimilar to be effective even if patent litigation has not concluded.

Amends the Federal Food, Drug, and Cosmetic Act to deem as misbranded a biotechnology-derived therapeutic protein if its labeling fails to meet specified requirements.

Cosponsors 2

Members who signed on, in the order they did. All signed on May 24, 2007.

SeatCosponsorSigned on
R-NCRichard BurrOriginalMay 24, 2007
R-OKTom CoburnOriginalMay 24, 2007

Committees 1

Where it was sent and what each committee and subcommittee did with it, in order.

ChamberCommitteeWhat it did
SenateHealth, Education, Labor, and Pensions Committee
Referred May 24, 2007

Actions 3

Everything that happened, newest first.

  1. May 24, 2007Introduced in Senate
  2. May 24, 2007Sponsor introductory remarks on measure. (CR S6867)
  3. May 24, 2007Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

In the Congressional Record 1

Days the Record’s own index lists this bill, newest first, with the pages and the members it names. Pages starting H are the House, S the Senate, E Extensions of Remarks.

WhereIn the RecordMembersDate
SenateDebate and remarks S6867Judd Gregg R-NH, Orrin G. Hatch R-UTMay 24, 2007

Research

What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.

CRS reports 1

Congressional Research Service work that CRS links to this bill or the law it became, newest first.

Cite it 1

Products on other subjects that cite it, usually among other measures.

ProductTitleKindPublished
RL34045FDA Regulation of Follow-On Biologics ArchivedReportApr 26, 2010

Titles 2

Every title it has carried, official and short, at each stage.

Official Title as Introduced
A bill to amend the Public Health Service Act to provide for the approval of biosimilars, and for other purposes.
Short Titles as Introduced
Affordable Biologics for Consumers Act

Subjects

Assigned by the Library of Congress. Policy area: Health.

Text 1

Each version as it was printed, newest first.

  1. May 24, 2007Introduced in Senate

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details.

Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.